ALERT!!! BUY TZYM Currently at $4.40 Target $12+ Accumulate anywhere below $7. We have learnt TZYM is about to announce a blockbuster new drug deal and discovery with a huge pharmaceutical company that will triple annual profits. When the news gets out main stream we expect the stock to explode in price to well north of $12. Once it explodes in price (within 4 weeks) it will be too late to make profits from this stock. Insiders and people in the âloopâ have already been accumulating this stock get in quick Accumulate any-where below $7 and hold on for $12+ STRONG BUY BELOW $7. Tranzyme, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of acute and chronic gastrointestinal (GI) motility disorders in the United States and internationally. The company’s clinical product candidates include ulimorelin, an intraveneous ghrelin agonist, which is in the Phase III clinical development stage for the treatment of acute upper GI motility disorders; and TZP-102, an orally-administered ghrelin agonist that has commenced Phase IIb clinical development stage for the treatment of diabetic gastroparesis. Its preclinical product candidates comprise TZP-201, a motilin antagonist for the treatment of various forms of moderate-to-severe diarrhea; and TZP-301, an oral ghrelin antagonist for the treatment of metabolic diseases.